29 May 2019
Visiongain has launched a new pharma report Global Pulmonary/Respiratory Drug Delivery Market Forecast 2019-2029: Suspension Aerosol, Solution Aerosol, Dry Powder Formulation, Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories, Plain Canister, Coated Canister, Asthma, COPD, Cystic Fibrosis, Other Applications, Hospitals & Clinics, Homecare Settings.
The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.
The lead analyst of the report commented "Technological advances in drug delivery will have a positive impact on the market for pulmonary drug delivery devices. These advances include the electronic dose counter MDI, incorporation of agglomerated vesicle technology, and technology for supercritical fluids. Moreover, increasing demand for advanced drug delivery devices, improving healthcare infrastructure, ease of use, and increase in healthcare spending are some of the major factors that will provide lucrative opportunities in the near future."
Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva and other companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.